GoodRx Holdings, Inc. (NASDAQ:GDRX) Position Boosted by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 38.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,228,836 shares of the company's stock after buying an additional 342,781 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.32% of GoodRx worth $5,714,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versor Investments LP purchased a new stake in shares of GoodRx during the fourth quarter valued at approximately $54,000. Verus Capital Partners LLC purchased a new stake in GoodRx during the 4th quarter worth $55,000. Steward Partners Investment Advisory LLC purchased a new stake in GoodRx during the 4th quarter worth $56,000. Aigen Investment Management LP acquired a new position in GoodRx in the 4th quarter worth $62,000. Finally, EP Wealth Advisors LLC purchased a new position in GoodRx in the 3rd quarter valued at about $73,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Performance

NASDAQ GDRX traded up $0.31 during trading hours on Wednesday, hitting $4.79. The company had a trading volume of 2,453,872 shares, compared to its average volume of 1,335,354. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.84 billion, a P/E ratio of -159.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The business has a fifty day simple moving average of $4.72 and a 200-day simple moving average of $5.46.

Remove Ads

Analyst Ratings Changes

GDRX has been the topic of several recent analyst reports. Morgan Stanley cut their price target on GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 17th. Wells Fargo & Company reduced their target price on GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Citigroup reduced their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. Mizuho assumed coverage on GoodRx in a research note on Wednesday, December 4th. They set a "neutral" rating and a $5.00 price objective on the stock. Finally, KeyCorp reduced their target price on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, GoodRx has a consensus rating of "Moderate Buy" and an average target price of $8.18.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.